Fluorfenidine F-18 is a radionucleotide used in positron emission tomography (PET) imaging procedures.

CHS-828 () is a potent and selective inhibitor of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in the biosynthesis of NAD, which may be used to deplete cells of Nicotinamide adenine dinucleotide (NAD). Early preclinical studies revealed a high in vitro activity of CHS 828 in human tumor cell lines, a low cross-reactivity with clinically used anticancer agents, and no significant sensitivity to some of the known mechanisms of resistance. In the subsequent pharmacodynamic evaluation, CHS 828 demonstrated significant antitumor activity in several in vivo tumor models, especially pronounced in a nude mouse model of small cell lung cancer. CHS 828 exerted a high antitumor activity on eight tumor samples derived from patients with ovarian cancer and chronic lymphocytic leukemia.

Guanoctine was studied as an antihypertensive agent.

Guancydine, an antihypertensive agent which anti-angiotensin effect was not observed.

Zaltidine (CP-57,361) is a guanidinothiazolylimidazole compound which is a highly specific H2-receptor antagonist. It potently inhibits gastric acid secretion. Zaltidine appears to be an effective treatment of duodenal ulcer in human studies. However, the incidence of hepatic damage (8%) seems higher than with commonly used H2-receptor antagonists.